DJO Global posted 4Q17 revenue of US $312.2MM, +5.3% vs. 4Q16, and 2017 of $1,186.1MM, +2.7% vs. 2016.
ORTHOWORLD estimates segment sales and growth as follows.
4Q17
4Q16
$ Change
% Change
Joint Reconstruction
$70.9
$58.1
$0.2
22.1%
Knee
$19.2
$15.4
$0.2
24.4%
Hip
$16.7
$14.0
$0.2
19.5%
Extremities
$35.0
$28.7
$0.2
22.2%
Other*
$241.3
$238.4
$0.0
5.3%
Total
$312.2
$296.5
$0.1
5.3%
2017
2016
$ Change
% Change
Joint Reconstruction
$253.6
$209.6
$43.9
21.0%
Knee
$68.1
$55.3
$12.7
23.0%
Hip
$60.3
$48.6
$11.7
24.2%
Extremities
$125.2
$105.7
$19.5
18.4%
Other*
$932.6
$945.7
-$13.2
-1.4%
Total
$1,186.1
$1,155.4
$30.8
2.7%
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Leadership expects orthopaedic product sales will continue to be a growth driver in 2018. New product launches for Surgical Implants will commence in 2Q in hip, knee and shoulder.
While not sold under the Surgical Implant segment, at AAOS DJO launched the X4 Smart knee brace for total knee arthroplasty that monitors patient recovery and compliance in real time, enabling on-demand patient/physician connectivity.
DJO Global posted 4Q17 revenue of US $312.2MM, +5.3% vs. 4Q16, and 2017 of $1,186.1MM, +2.7% vs. 2016.
ORTHOWORLD estimates segment sales and growth as follows.
Q17 Q16 $ Change % Change
Joint Reconstruction...
DJO Global posted 4Q17 revenue of US $312.2MM, +5.3% vs. 4Q16, and 2017 of $1,186.1MM, +2.7% vs. 2016.
ORTHOWORLD estimates segment sales and growth as follows.
4Q17
4Q16
$ Change
% Change
Joint Reconstruction
$70.9
$58.1
$0.2
22.1%
Knee
$19.2
$15.4
$0.2
24.4%
Hip
$16.7
$14.0
$0.2
19.5%
Extremities
$35.0
$28.7
$0.2
22.2%
Other*
$241.3
$238.4
$0.0
5.3%
Total
$312.2
$296.5
$0.1
5.3%
2017
2016
$ Change
% Change
Joint Reconstruction
$253.6
$209.6
$43.9
21.0%
Knee
$68.1
$55.3
$12.7
23.0%
Hip
$60.3
$48.6
$11.7
24.2%
Extremities
$125.2
$105.7
$19.5
18.4%
Other*
$932.6
$945.7
-$13.2
-1.4%
Total
$1,186.1
$1,155.4
$30.8
2.7%
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Leadership expects orthopaedic product sales will continue to be a growth driver in 2018. New product launches for Surgical Implants will commence in 2Q in hip, knee and shoulder.
While not sold under the Surgical Implant segment, at AAOS DJO launched the X4 Smart knee brace for total knee arthroplasty that monitors patient recovery and compliance in real time, enabling on-demand patient/physician connectivity.
Copy to clipboard 
